Naoki Furuya

2.4k total citations · 1 hit paper
89 papers, 827 citations indexed

About

Naoki Furuya is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Naoki Furuya has authored 89 papers receiving a total of 827 indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Naoki Furuya's work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Diagnosis and Treatment (27 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Naoki Furuya is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Diagnosis and Treatment (27 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Naoki Furuya collaborates with scholars based in Japan, United States and Taiwan. Naoki Furuya's co-authors include Masamichi Mineshita, Teruomi Miyazawa, Kazumi Nishino, Takeo Inoue, Koichi Azuma, Satoshi Morita, Kei Morikawa, Satoshi Ikeda, Terufumi Kato and Shunsuke Teraoka and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Naoki Furuya

77 papers receiving 818 citations

Hit Papers

Recen... 2025 2026 2025 5 10 15
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recent advances in therapeutic strategies for non-small cell lung cancer
    2025 15 citations Naoki Furuya et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoki Furuya Japan 16 590 510 181 126 72 89 827
Arunee Dechaphunkul Thailand 13 520 0.9× 468 0.9× 190 1.0× 156 1.2× 152 2.1× 62 855
Ramón Palmero Spain 14 328 0.6× 384 0.8× 159 0.9× 79 0.6× 62 0.9× 50 646
Kentaro Ito Japan 14 473 0.8× 400 0.8× 213 1.2× 112 0.9× 44 0.6× 66 699
Masahiro Morise Japan 17 752 1.3× 707 1.4× 206 1.1× 141 1.1× 124 1.7× 112 1.1k
Katherine A. Scilla United States 11 290 0.5× 363 0.7× 136 0.8× 162 1.3× 47 0.7× 25 583
Esther Zamora Spain 10 576 1.0× 756 1.5× 203 1.1× 277 2.2× 42 0.6× 22 1.0k
Lambros Vamvakas Greece 17 370 0.6× 597 1.2× 114 0.6× 164 1.3× 71 1.0× 44 759
Naoko Miura Japan 17 514 0.9× 459 0.9× 224 1.2× 125 1.0× 123 1.7× 62 919
Alessandro Bertolini Italy 11 532 0.9× 515 1.0× 124 0.7× 65 0.5× 103 1.4× 22 760
Francesca Mazzoni Italy 18 470 0.8× 568 1.1× 178 1.0× 160 1.3× 67 0.9× 63 821

Countries citing papers authored by Naoki Furuya

Since Specialization
Citations

This map shows the geographic impact of Naoki Furuya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Furuya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Furuya more than expected).

Fields of papers citing papers by Naoki Furuya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Furuya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Furuya. The network helps show where Naoki Furuya may publish in the future.

Co-authorship network of co-authors of Naoki Furuya

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Furuya. A scholar is included among the top collaborators of Naoki Furuya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Furuya. Naoki Furuya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations
2.
Furuya, Naoki, T Hotta, Toshihide Yokoyama, et al.. (2025). Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐ VTE / NEJ037 Study. Cancer Medicine. 14(1). e70568–e70568. 1 indexed citations
3.
Kogure, Yoshihito, Hiroya Hashimoto, Haruko Daga, et al.. (2024). Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. JTO Clinical and Research Reports. 6(3). 100784–100784.
4.
Nakamichi, Shinji, Kaoru Kubota, Toshihiro Misumi, et al.. (2024). Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study). Clinical Cancer Research. 30(6). 1104–1110. 8 indexed citations
5.
Yamamoto, Hiroyuki, Hiroyuki Takeda, Yasuyuki Kojima, et al.. (2024). An approach for improvement of the accuracy of cancer gene panel testing. International Journal of Clinical Oncology. 29(5). 571–581. 2 indexed citations
6.
7.
8.
Kondo, Tetsuro, Kaoru Kubota, Shinji Nakamichi, et al.. (2023). 1294P A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study). Annals of Oncology. 34. S746–S747. 1 indexed citations
9.
Akamatsu, Hiroaki, Shunsuke Teraoka, Shinkichi Takamori, et al.. (2022). Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research. 28(15). 3207–3213. 22 indexed citations
10.
Shimokawa, Tsuneo, Yuichi Takiguchi, Toshihiro Misumi, et al.. (2022). A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630. Clinical Cancer Research. 28(20). 4402–4409. 19 indexed citations
11.
Tsubata, Yukari, Kosuke Hamai, Naoki Furuya, et al.. (2022). Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data. International Journal of Clinical Oncology. 28(1). 69–78. 11 indexed citations
12.
Ito, Kentaro, Masahiro Morise, Kazushige Wakuda, et al.. (2021). A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open. 6(3). 100115–100115. 33 indexed citations
13.
14.
Tanimoto, Azusa, Shingo Matsumoto, Shinji Takeuchi, et al.. (2020). Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression. Clinical Cancer Research. 27(5). 1410–1420. 38 indexed citations
15.
Nishimura, Toshihide, Haruhiko Nakamura, Ayako Yachie‐Kinoshita, et al.. (2020). Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Scientific Reports. 10(1). 10881–10881. 8 indexed citations
16.
Zenke, Yoshitaka, Shingo Matsumoto, Naoki Furuya, et al.. (2020). Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).. Journal of Clinical Oncology. 38(15_suppl). 9589–9589. 10 indexed citations
17.
Furuya, Naoki, Kentaro Ito, Tadashi Sakaguchi, et al.. (2020). The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Oncology. 98(9). 661–668. 5 indexed citations
18.
Zenke, Yoshitaka, Shingo Matsumoto, Terufumi Kato, et al.. (2020). Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III locally advanced non-small cell lung cancer patients.. Journal of Clinical Oncology. 38(15_suppl). 9038–9038. 3 indexed citations
19.
20.
Morikawa, Kei, et al.. (2012). A Case of Squamous Cell Lung Carcinoma with Bone Metastasis Responding to Denosumab After Zoledronic Acid Hydrate. Haigan. 52(7). 1035–1040. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arunee Dechaphunkul Breakdown of academic impact, for papers by Ramón Palmero Breakdown of academic impact, for papers by Kentaro Ito Breakdown of academic impact, for papers by Masahiro Morise Breakdown of academic impact, for papers by Katherine A. Scilla Breakdown of academic impact, for papers by Esther Zamora Breakdown of academic impact, for papers by Lambros Vamvakas Breakdown of academic impact, for papers by Naoko Miura Breakdown of academic impact, for papers by Alessandro Bertolini Breakdown of academic impact, for papers by Francesca Mazzoni
Rankless by CCL
2026